Bauduer M; Gribben J; Herrmann R; Thiel E; Rai K; Larson R; Ferrara F; Barnard J; Pearce H; Taylor C; Brillant C; Steurer M; Weingart O; Flinn IW; Funkhouser A; Tallman M; Sun Z; Jaksic B; Suciu S; Chevret S; Dighiero G; Leporrier M; Frankel SR; Sirard C; Hillmen P; Trehu B; Felder M; Busch R; Eichhorst B; Hallek M; Stilgenbauer S; Pangalis G; Bezares R; van Oers MH; van Putten W; Gobbi M; Spriano M; Mabed M; Catovsky D; Richards S; Wade R; Abdelhamid T; Dearden C; Knauf W; Blonski J; Jamroziak K; Robak T; Mauro F; Hiddeman W; Johnson SA; Longthorne G; Juliusson G; Pulluqi P; Zinzani PL; Pozzato G; Oncology US; Reynolds C; Furman RR; Durrant J; Elphinstone P; Evans V; Gettins L; Hicks C; James S; Clarke M; MacKinnon L; McHugh TM; Morris P; Read S; Gregory C.
CLL Trialists’ Collaborative Group, Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials, «HAEMATOLOGICA», 2012, 97, pp. 428 - 436 [Scientific article]
Gazzola A; Sista MT; Agostinelli C; Righi S; Sapienza MR; Mannu C; Rossi M; Bacci F; Sabattini E; Went P; Zinzani PL; Pileri SA; Piccaluga PP., CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified., «JOURNAL OF CLINICAL PATHOLOGY», 2011, 64, pp. 83 - 87 [Scientific article]
Ferreri AJ; Zinzani PL; Govi S; Pileri S.A., Enteropathy-associated T-cell lymphoma., «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2011, 79, pp. 84 - 90 [Scientific article]
Zinzani PL; Gandolfi L; Broccoli A; Argnani L; Fanti S; Pellegrini C; Stefoni V; Derenzini E; Quirini F; Baccarani M., Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma., «CANCER», 2011, 117, pp. 1010 - 1018 [Scientific article]
Roncolato F.; Gazzola A.; Zinzani P.L.; Pileri S.A.; Piccaluga P.P., Targeted molecular therapy in peripheral T-cell lymphomas, «EXPERT REVIEW OF HEMATOLOGY», 2011, 4, pp. 551 - 562 [Scientific article]
Vitolo U.; Barosi G.; Fanti S.; Gianni A.M.; Martelli M.; Petrini M.; Zinzani P.L.; Tura S., Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology., «AMERICAN JOURNAL OF HEMATOLOGY», 2010, 85(2), pp. 147 - 155 [Scientific article]
Lopci E; Santi I; Tani M; Maffione AM; Montini G; Castellucci P; Stefoni V; Rubello D; Fonti C; Zinzani P; Fanti S., FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma., «THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING», 2010, 54, pp. 436 - 441 [Scientific article]
Zinzani PL; Broccoli A; Stefoni V; Musuraca G; Abruzzese E; De Renzo A; Cantonetti M; Bacci F; Baccarani M; Pileri SA., Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients., «CANCER», 2010, 116, pp. 5667 - 5675 [Scientific article]
Zinzani P.L.; Rossi G.; Franceschetti S.; Botto B.; Di Rocco A.; Cabras M.G.; Petti M.C.; Stefoni V.; Broccoli A.; Fanti S.; Pellegrini C.; Montini G.C.; Gandolfi L.; Derenzini E.; Argnani L.; Fina M.; Tucci A.; Bottelli C.; Pileri S.; Baccarani M., Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients., «CLINICAL CANCER RESEARCH», 2010, 16(15), pp. 3998 - 4004 [Scientific article]
Zinzani P.L.; Gandolfi L.; Stefoni V.; Fanti S.; Fina M.; Pellegrini C.; Montini G.C.; Derenzini E.; Broccoli A.; Argnani L.; Pileri S.; Baccarani M., Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome., «CLINICAL LYMPHOMA MYELOMA & LEUKEMIA», 2010, 10(4), pp. 258 - 261 [Scientific article]
Piccaluga PP; Sapienza MR; Agostinelli C; Sagramoso C; Mannu C; Sabattini E; Zinzani PL; Pileri SA., Biology and treatment of follicular lymphoma., «EXPERT REVIEW OF HEMATOLOGY», 2009, 2 (5), pp. 533 - 547 [Scientific article]
Derenzini E; Stefoni V; Pellegrini C; Fina MP; Broccoli A; Venturini F;
Gandolfi L; Pileri SA; Martelli M; Petti MC; Perrotti A; De Renzo A; Zaja F;Baccarani M; Zinzani PL., Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. Leuk Lymphoma., «LEUKEMIA & LYMPHOMA», 2009, 50(11), pp. 1824 - 1829 [Scientific article]
Crea F; Giovannetti E; Zinzani PL; Danesi R., Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization., «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2009, 72(1), pp. 21 - 44 [Scientific article]
Zinzani P.L.; Stefoni V.; Tani M.; Fanti S.; Musuraca G.; Castellucci P.; Marchi E.; Fina M.; Ambrosini V.; Pellegrini C.; Alinari L.; Derenzini E.; Montini G.; Broccoli A.; Bacci F.; Pileri S.; Baccarani M., Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma, «JOURNAL OF CLINICAL ONCOLOGY», 2009, 27(11), pp. 1781 - 1787 [Scientific article]
Zinzani PL; Tani M; Fanti S; Stefoni V; Musuraca G; Castellucci P; Marchi E; Farsad M; Fina M; Pellegrini C; Alinari L; Derenzini E; de Vivo A; Bacci F; Pileri S; Baccarani M., A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients., «ANNALS OF ONCOLOGY», 2008, 19, pp. 769 - 773 [Scientific article]
